All In Biotech

Drug Trial Radar · NCT02778919

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

Last checked: Nov 19, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

Not stated

Start

May 9, 2016

Primary completion

Mar 23, 2018

Study completion Mar 23, 2018

Sponsor

Sponsor type
Industry
First posted
May 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Who can join
Female only, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship of KLH-2109 compared to placebo in Japanese patients with endometriosis.

Conditions

  • Endometriosis

Interventions

  • KLH-2109Drug

  • PlaceboDrug

  • Leuprorelin acetateDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of average Numerical Rating Scale (NRS) score of pelvic painTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Multiple Locations, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.